Programming gene and engineered-cell therapies with synthetic biology
Abstract
Advances in synthetic biology are enabling the development of new gene and cell therapies. Kitada et al. review recent successes in areas such as cancer immunotherapy and stem cell therapy, point out the limitations of current approaches, and describe prospects for using synthetic biology to overcome these challenges. Broader adoption of these therapies requires precise, context-specific control over cellular behavior. Gene circuits can be built to give sophisticated control over cellular behaviors so that therapeutic functions can, for example, be programmed to activate in response to disease biomarkers.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Feb 09, 2018
- Source ID
- 10.1126/science.aad1067
Entities
People
- Breanna DiAndreth
- Brian Teague
- Ron Weiss
- Tasuku Kitada
Organizations
- Massachusetts Institute of Technology
- National Institutes of Health
- National Science Foundation
- Phillip T. and Susan M. Ragon Institute